Fractyl Health (GUTS) Stock
Developer of minimally invasive treatments for metabolic disease. Here's the price, business snapshot, and what's worth knowing about Fractyl Health in July 2026.
Fractyl Health, Inc. (GUTS) is a small‑cap healthcare company developing endoscopic therapies aimed at treating metabolic diseases such as type 2 diabetes and obesity. The business focuses on minimally invasive procedures that seek to improve metabolic control as an alternative to pharmaceutical or surgical approaches. Investors should note Fractyl is in a development and early commercialisation phase: progress depends on clinical trial outcomes, regulatory decisions and payer reimbursement. With a market capitalisation of about $176.64 million, the stock can be volatile and is typically regarded as speculative. Key value drivers include trial readouts, regulatory milestones, partnership activity and adoption by clinicians and payers. Key risks include clinical setbacks, regulatory delays, funding requirements and potential dilution. This summary is for educational purposes only; it is not investment advice. Investors should consider their risk tolerance, time horizon and diversification needs, and consult a regulated financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying shares of Fractyl Health with a target price significantly higher than its current value.
Financial Health
FRACTYL HEALTH INC is performing well with strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GUTS
Obesity Drug Distribution via Telehealth Platforms Explained
Novo Nordisk has launched a discounted telehealth subscription model for its popular Wegovy treatments to counter rising competition. This shift creates compelling investment opportunities in the digital health platforms that are becoming vital distribution channels for blockbuster obesity drugs.
Published: 1 April 2026
Explore BasketObesity Drug Stocks: Medicare Coverage Trade-offs
A new agreement between the Trump administration, Eli Lilly, and Novo Nordisk will dramatically lower the cost of GLP-1 weight loss drugs and expand Medicare coverage. This move is expected to significantly increase patient access and boost sales, creating opportunities for the drug manufacturers and their key suppliers.
Published: 7 November 2025
Explore BasketBiotech Buyout Wave Targets Obesity Market 2025
Pfizer's bid for obesity drug maker Metsera has turned into a legal battle after a counteroffer from Novo Nordisk, highlighting the fierce competition in the weight-loss market. This intense M&A activity signals that other biotech companies with promising obesity treatments could become the next valuable acquisition targets.
Published: 1 November 2025
Explore BasketWeight-Loss Drug M&A: Valuation Risk Concerns
Novo Nordisk's superior bid for Metsera has ignited a bidding war with Pfizer, highlighting the intense M&A activity in the obesity drug market. This theme focuses on other biotech companies with promising weight-loss therapies that could become the next acquisition targets.
Published: 31 October 2025
Explore BasketOzempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketWeight-Loss Drug Shakeup: What's Next for Biotechs?
Following former President Trump's pledge to slash prices for popular weight-loss drugs, uncertainty has hit major pharmaceutical stocks. This theme identifies competitor firms and biotechs that could gain an edge as the pricing landscape for metabolic drugs shifts.
Published: 18 October 2025
Explore BasketBeyond The Needle: The Oral GLP-1 Revolution
Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published: 28 August 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: 27 August 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: 19 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Trial readouts and regulatory milestones could move the share price; outcomes are uncertain and the stock may be volatile.
Innovative therapy approach
Endoscopic metabolic treatments aim to offer a less invasive option to surgery, but commercial adoption depends on evidence, approvals and payer support.
Large potential market
If widely adopted, these treatments target a substantial global market for metabolic disease, though execution and reimbursement are key risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
